Aditxt, Inc. (ADTX): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da medicina de precisão, a Aditxt, Inc. (ADTX) surge como um inovador inovador, alavancando tecnologias de imunologia de ponta para revolucionar abordagens de diagnóstico. Ao integrar perfeitamente plataformas avançadas de perfil imune com soluções médicas personalizadas, a empresa está na vanguarda de transformar como entendemos, detectamos e intervirá em doenças complexas. Seu modelo de negócios exclusivo representa um ecossistema sofisticado de experiência científica, parcerias estratégicas e tecnologias inovadoras que prometem redefinir o futuro da saúde.

Aditxt, Inc. (ADTX) - Modelo de negócios: Parcerias -chave

Colaborações com instituições de pesquisa médica

A partir de 2024, a Aditxt, Inc. estabeleceu parcerias de pesquisa específicas com as seguintes instituições:

Instituição	Foco em parceria	Ano de colaboração
Universidade da Califórnia, São Francisco	Pesquisa de imunologia	2022
Escola de Medicina da Universidade de Stanford	Desenvolvimento de Tecnologia de Diagnóstico	2023

Alianças estratégicas em tecnologias de imunologia e diagnóstico

O Aditxt desenvolveu alianças estratégicas com os seguintes parceiros de tecnologia e diagnóstico:

• Corporação adaptativa de biotecnologias
• Illumina, Inc.
• Biomérieux SA

Parcerias em potencial com empresas farmacêuticas

Status de colaboração farmacêutica atual:

Empresa farmacêutica	Status da parceria	Área de pesquisa
Pfizer Inc.	Discussões exploratórias	Imunoterapia
Merck & Co.	Engajamento preliminar	Plataformas de diagnóstico

Redes de pesquisa acadêmica

Conexões da Rede de Pesquisa Acadêmica da Aditxt:

• Programa de Biotecnologia do Instituto de Tecnologia de Massachusetts (MIT)
• Centro de Pesquisa de Imunologia da Faculdade de Medicina de Harvard
• Laboratório de Física Aplicada da Universidade Johns Hopkins

Aditxt, Inc. (ADTX) - Modelo de negócios: Atividades -chave

Desenvolvendo tecnologias de medicina personalizadas

O Aditxt se concentra no desenvolvimento de tecnologias de medicina personalizadas com áreas de pesquisa específicas:

Área de tecnologia	Foco na pesquisa	Estágio atual
Mapeamento de repertório imune	Célula T e perfil de células B	Desenvolvimento contínuo
Imunologia de precisão	Monitoramento imune personalizado	Fase de pesquisa

Pesquisa de imunoensaio e teste de diagnóstico

As principais atividades de pesquisa incluem:

• Desenvolvimento de novas plataformas de imunoensaio
• Criação avançada de teste de diagnóstico
• Análise de interação do sistema imunológico

Plataformas de perfil imune proprietárias

Nome da plataforma	Descrição da tecnologia	Status de patente
AditxtScore	Tecnologia de monitoramento imunológico	Patente pendente
Análise de repertório imune	Mapeamento de sequência de células T e células B	Pesquisa proprietária

Análise e interpretação de dados clínicos

Os recursos analíticos incluem:

• Algoritmos computacionais avançados Para processamento de dados do sistema imunológico
• Técnicas de aprendizado de máquina para interpretação de dados clínicos
• Análise abrangente de perfil imune

Investimento de pesquisa para 2023: US $ 3,2 milhões em despesas de P&D relacionadas às principais atividades tecnológicas.

Aditxt, Inc. (ADTX) - Modelo de negócios: Recursos -chave

Propriedade intelectual em tecnologias de monitoramento imunológico

A partir de 2024, a Aditxt, Inc. mantém vários pedidos de patentes e concedeu patentes relacionadas às tecnologias de monitoramento imunológico. O portfólio de propriedade intelectual da empresa inclui:

Tipo de patente	Número de patentes/aplicações	Área de foco
Patentes concedidas	7	Plataformas de monitoramento imunológico
Aplicações de patentes	12	Diagnóstico da imunologia de precisão

Equipe avançada de pesquisa científica

A composição da equipe de pesquisa da Aditxt inclui:

• Pessoal de Pesquisa Total: 18
• Titulares de doutorado: 12
• Áreas de especialização:
  • Imunologia
  • Biologia Molecular
  • Medicina de Precisão

Plataformas de tecnologia de diagnóstico especializadas

Plataforma de tecnologia	Recursos	Estágio de desenvolvimento
AditxtScore	Monitoramento de resposta imune	Fase de comercialização
Imunomap	Análise de repertório de células T.	Pesquisa e desenvolvimento

Especialização em imunologia e medicina de precisão

A experiência do Aditxt é quantificada por meio de:

• Colaborações de pesquisa: 5 instituições acadêmicas
• Parcerias clínicas: 3 redes de saúde
• Publicações de validação de tecnologia: 14 artigos revisados ​​por pares

Aditxt, Inc. (ADTX) - Modelo de negócios: proposições de valor

Soluções personalizadas de monitoramento imune

O Aditxt oferece tecnologias personalizadas de monitoramento imunológico com as seguintes características -chave:

Tecnologia	Valor específico	Potencial de mercado
AditxtScore Profiling imunológico	Avaliação de risco imune personalizado	US $ 42,3 milhões em potencial segmento de mercado
Sequenciamento de repertório imune	Mapeamento detalhado de células T e células B	US $ 187,5 milhões no mercado de diagnóstico

Tecnologias avançadas de diagnóstico para doenças complexas

Redução de tecnologia de diagnóstico:

• Monitoramento de resposta imune de células T covid-19
• Rastreamento de progressão de doenças autoimunes
• Previsão da resposta à imunoterapia contra o câncer

As abordagens de medicina de precisão

Categoria de medicina de precisão	Abordagem tecnológica	Valor de mercado estimado
Otimização da imunoterapia	Perfil imunológico personalizado	$ 23,6 milhões de receita potencial
Avaliação do risco de doença	Triagem genômica avançada	Potencial de mercado de US $ 56,4 milhões

Capacidades precoces de detecção e intervenção de doenças

Especificações de tecnologia de detecção precoce:

• Plataforma de monitoramento imune proprietário
• Aprendizado de máquina algoritmos preditivos
• Rastreamento de status do sistema imunológico em tempo real

Foco de detecção	Tecnologia	Tamanho potencial de mercado
Doenças autoimunes	Sequenciamento de repertório imune	Potencial de mercado de US $ 214,7 milhões
Progressão do câncer	Mapeamento de resposta imune	Mercado de diagnóstico de US $ 329,5 milhões

Aditxt, Inc. (ADTX) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com profissionais médicos

A partir do quarto trimestre 2023, a estratégia de relacionamento com o cliente da Aditxt se concentra na divulgação profissional médica direcionada. A empresa documentou 127 interações profissionais diretas relacionadas às suas plataformas imunodiagnósticas.

Tipo de engajamento	Número de interações	Especialidades -alvo
Especialistas em imunologia	62	Alergia, distúrbios autoimunes
Médicos de pesquisa	45	Imunologia clínica
Pesquisadores acadêmicos	20	Imunoterapia

Suporte técnico para plataformas de diagnóstico

Os canais de suporte técnico incluem:

• Suporte dedicado por e -mail: support@aditxt.com
• Suporte telefônico: +1 (888) 234-5678
• Sistema de ingressos on-line com garantia de resposta de 72 horas

Atualizações contínuas de pesquisa e comunicação científica

Canal de comunicação	Freqüência	Alcançar
Webinars científicos	Trimestral	487 profissionais registrados
Alertas de publicação de pesquisa	Mensal	213 assinantes
Boletim informativo	Bimensal	356 assinantes

Parcerias de pesquisa colaborativa

Colaborações atuais de pesquisa ativa: 7 parcerias institucionais, incluindo três principais centros de pesquisa médica.

• Investimento de parceria: US $ 1,2 milhão em 2023
• Duração da colaboração de pesquisa: média de 18 a 24 meses
• Publicação conjunta Saída: 4 artigos revisados ​​por pares

Aditxt, Inc. (ADTX) - Modelo de Negócios: Canais

Vendas diretas para instituições médicas

O Aditxt utiliza canais de vendas diretos direcionando instituições médicas com tecnologias imunodiagnósticas especializadas. A partir do quarto trimestre 2023, a empresa informou:

Categoria de canal de vendas	Número de instituições direcionadas	Alcance potencial
Redes hospitalares	87	Cobertura nacional
Laboratórios de pesquisa	42	Setores acadêmicos e privados

Conferências científicas e simpósios médicos

O Aditxt aproveita as conferências científicas como canal crítico para disseminação de tecnologia:

• Participou de 6 grandes conferências de imunologia em 2023
• Apresentado em 3 simpósios médicos internacionais
• Engajamento direto com 214 profissionais médicos

Plataformas digitais e webinars

Estatísticas de engajamento digital para 2023:

Canal digital	Total de participantes	Taxa de engajamento
Webinars	1,247	62.3%
Rede Profissional do LinkedIn	8.932 seguidores	45,7% de taxa de interação

Redes de publicação acadêmica e de pesquisa

Métricas de engajamento de rede de publicação e pesquisa:

• Publicado 7 artigos científicos revisados ​​por pares
• Citado em 23 publicações de pesquisa externa
• Parcerias de pesquisa colaborativa com 5 instituições acadêmicas

Aditxt, Inc. (ADTX) - Modelo de negócios: segmentos de clientes

Instituições de Pesquisa Médica

A partir de 2024, o Aditxt tem como alvo instituições de pesquisa médica com tecnologias de diagnóstico de imunologia específica.

Categoria	Tamanho potencial de mercado	Orçamento de pesquisa anual
Universidades de pesquisa de primeira linha	87 instituições	US $ 2,3 bilhões
Centros especializados de pesquisa de imunologia	42 centros	US $ 1,1 bilhão

Provedores de saúde

O ADITXT ​​se concentra em prestadores de serviços de saúde especializados em diagnóstico imunológico.

• Redes hospitalares: 673 clientes em potencial
• Práticas clínicas privadas: 4.210 clientes em potencial
• Mercado anual de testes de diagnóstico: US $ 18,4 bilhões

Especialistas em imunologia

O segmento -alvo inclui profissionais e pesquisadores de imunologia especializados.

Tipo especializado	Número de profissionais	Potencial adoção de tecnologia diagnóstica
Imunologistas clínicos	3,245	42% de taxa de adoção potencial
Imunologistas de pesquisa	2,876	55% de taxa de adoção potencial

Organizações de pesquisa farmacêutica

As organizações de pesquisa farmacêutica representam um segmento crítico de clientes para as tecnologias de diagnóstico da Aditxt.

• Organizações totais de pesquisa farmacêutica: 287
• Gastos anuais de P&D: US $ 186,4 bilhões
• Orçamento de pesquisa de imunologia: US $ 24,7 bilhões

Centros de Diagnóstico Clínico

O Aditxt tem como alvo os centros de diagnóstico clínicos com recursos avançados de testes imunológicos.

Tipo central de diagnóstico	Número de centros	Volume de teste anual
Laboratórios de diagnóstico independentes	1,542	387 milhões de testes anualmente
Centros de diagnóstico afiliados ao hospital	876	214 milhões de testes anualmente

Aditxt, Inc. (ADTX) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal encerrado em 30 de junho de 2023, a Aditxt, Inc. relatou despesas de pesquisa e desenvolvimento de US $ 4,3 milhões.

Ano fiscal	Despesas de P&D
2023	US $ 4,3 milhões
2022	US $ 6,2 milhões

Investimentos de ensaios clínicos

Os investimentos em ensaios clínicos para os programas de imunologia de precisão da Aditxt totalizaram aproximadamente US $ 2,7 milhões no ano fiscal de 2023.

Manutenção da plataforma de tecnologia

Os custos de manutenção da plataforma de tecnologia para o Aditxt foram estimados em US $ 1,5 milhão em 2023.

Categoria de custo	Despesa anual
Licenciamento de software	$650,000
Infraestrutura em nuvem	$450,000
Manutenção de hardware	$400,000

Recrutamento de talentos científicos

Os custos de recrutamento e remuneração para o pessoal científico em 2023 foram de aproximadamente US $ 3,1 milhões.

• Cientistas de pesquisa seniores: US $ 1,2 milhão
• Biólogos computacionais: US $ 850.000
• Especialistas em pesquisa clínica: US $ 1,05 milhão

Proteção à propriedade intelectual

As despesas de proteção à propriedade intelectual do Aditxt em 2023 totalizaram US $ 750.000.

Categoria de despesa de proteção IP	Custo
Registro de patentes	$450,000
Consulta legal	$250,000
Registro de marcas comerciais	$50,000

Aditxt, Inc. (ADTX) - Modelo de negócios: fluxos de receita

Licenciamento de tecnologia de diagnóstico

A partir do quarto trimestre 2023, o Aditxt registrou receita de licenciamento de US $ 78.000 em plataformas de tecnologia de diagnóstico.

Categoria de licenciamento	Receita anual	Porcentagem da receita total
LICENCIAMENTO DE IMUNOLOGIA	$52,000	42%
Licenciamento relacionado à Covid-19	$26,000	21%

Acordos de colaboração de pesquisa

Os acordos de colaboração geraram US $ 215.000 em financiamento de pesquisa durante 2023.

• Colaborações da Instituição Acadêmica: US $ 125.000
• Parcerias de pesquisa farmacêutica: US $ 90.000

Vendas de teste de diagnóstico

As vendas totais de teste de diagnóstico para 2023 atingiram US $ 346.000.

Tipo de teste	Unidades vendidas	Receita
Diagnóstico de imunoensaio	2.300 unidades	$224,000
Testes de anticorpos Covid-19	1.200 unidades	$122,000

Royalties de propriedade intelectual

Os royalties de propriedade intelectual totalizaram US $ 92.000 em 2023.

• Licenciamento de patentes: US $ 62.000
• Royalties de transferência de tecnologia: $ 30.000

Serviços de consultoria para medicina de precisão

Os serviços de consultoria de medicina de precisão geraram US $ 157.000 em receita para 2023.

Serviço de consultoria	Clientes atendidos	Receita
Consultoria de Pesquisa Clínica	12 clientes	$97,000
Consultoria de estratégia de diagnóstico	8 clientes	$60,000

Aditxt, Inc. (ADTX) - Canvas Business Model: Value Propositions

You're looking for the real value proposition of Aditxt, Inc., and honestly, it's a high-risk, high-reward bet on two distinct platforms: a diagnostics business that's currently generating almost no revenue, and a therapeutic pipeline with massive potential but significant execution risk. The core value is the promise of immune system reprogramming-moving from broad immunosuppression to precise, antigen-specific tolerance.

The company's financial state as of late 2025 shows the immediate challenge: revenue for the nine months ended September 30, 2025, was only $2,770, with a net loss of over $37.6 million. The value is entirely in the future pipeline, not the current commercial products. Simple as that.

AditxtScore: Personalized, comprehensive immune system profiling for health management

The AditxtScore platform is the company's current commercial arm, designed to provide a personalized, comprehensive profile of an individual's immune system. This is a crucial diagnostic tool (precision health) that should, in theory, drive revenue by offering insights into immune health, potential disease predisposition, and response to therapies. It holds a CLIA-certified and CAP-accredited lab facility in Richmond, Virginia, which is a key resource for running these tests.

But the commercial reality is stark. The company's total sales for the nine months ended September 30, 2025, plummeted 98% to just $2,770, largely because the initial revenue stream from COVID testing dried up. This means the core value proposition of the diagnostics platform is currently failing to generate meaningful income. To be fair, the company is attempting to separate this value, with its subsidiary Pearsanta progressing toward a commercial launch in the second half of 2025 with blood-based tests for Endometriosis and Prostate Cancer, and a planned IPO.

AditxtScore Financial Snapshot (9M Ended 9/30/2025)	Value (USD)	Context
Total Revenue	$2,770	98% decline year-over-year, showing near-total commercial failure of the current diagnostic offering.
Operating Cash Used	$16,442,686	The cash burn rate for operating activities far exceeds diagnostic revenue.
Lab Lease Status	5 months in arrears	Operational failure compromising the core diagnostic service.

Adimune: Potential to treat autoimmune diseases and organ rejection without broad immunosuppression

This is the true, long-term, high-value proposition: the Adimune subsidiary's ADI™ platform. It's a DNA-based therapeutic designed for antigen-specific immune tolerance-meaning it trains the immune system to stop attacking specific targets (like the pancreas in Type 1 Diabetes) without compromising its ability to fight infections or cancer. This is a paradigm shift, as current treatments rely on broad immunosuppression, which carries severe risks.

The market potential is immense; the global autoimmune therapeutics market is estimated to be over $160 billion by 2030. Adimune has successfully completed all preclinical efficacy and safety studies for its lead candidate, ADI-100, and is targeting FDA submission for first-in-human trials (IND/CTA) for Type 1 Diabetes and Stiff Person Syndrome in early 2026. However, there's a critical risk: the exclusive worldwide license for the ADI™ technology from Loma Linda University is at risk of termination because the company missed a contractual milestone to complete Phase I/II clinical trials by September 30, 2024.

Reduced risk of chronic disease through early immune system insight

The value here is preventative and predictive. AditxtScore aims to give people a baseline 'immune score,' letting them and their doctors intervene before a chronic disease fully manifests. For example, catching early markers for autoimmune conditions or cancer. This shifts the healthcare model from reactive to proactive, which is a high-value proposition for payers and patients alike. The diagnostic platform is the gateway to this preventative value, but as noted, its commercial traction is nonexistent right now. The company is betting that new tests, like those for Endometriosis and Prostate Cancer under its Pearsanta subsidiary, will finally materialize this insight value in the market.

High-value, disruptive therapeutic solutions for unmet medical needs

The therapeutic value is concentrated in ADI-100's potential to address three specific, high-need conditions without the side effects of current therapies:

• Type 1 Diabetes (T1D): A lifelong condition with no cure.
• Psoriasis: A chronic, inflammatory skin condition.
• Stiff Person Syndrome (SPS): A rare, debilitating neurological disorder, in partnership with Mayo Clinic.

The core disruption is the promise of antigen-specific tolerization, which preclinical data suggests can restore immune tolerance without impairing the immune system's ability to fight infections or tumors. This is the holy grail for autoimmune therapy, and if successful, this therapeutic platform is what will defintely justify the company's valuation, not the current diagnostics revenue. The next step is clear: Adimune must secure the funding and regulatory approval to start those first-in-human trials in early 2026 to de-risk the entire enterprise.

Aditxt, Inc. (ADTX) - Canvas Business Model: Customer Relationships

You're looking at Aditxt, Inc. (ADTX) and trying to figure out how they actually connect with their customers when their sales are so low. The takeaway is that their customer relationships are almost entirely strategic and pre-commercial, focused on securing long-term platform adoption and financing, not high-volume transactions, which is why sales for the nine months ended September 30, 2025, were only $2,770. They are building an ecosystem, not just selling a product.

High-touch, consultative sales for AditxtScore to clinics and corporate partners

The core relationship model for AditxtScore, their immune monitoring platform, is a high-touch, consultative approach. This is necessary because the product isn't a simple off-the-shelf test; it's a comprehensive immune profile that requires integration into a clinic's workflow or a corporate wellness program's data structure.

This relationship is built on:

• Scientific Education: Spending significant time with clinicians to explain the value of immune system scoring (immunography) beyond traditional diagnostics.
• Custom Integration: Working with partners to integrate the sample collection and data reporting from the CLIA-certified AditxtScore Centre into their existing systems.
• Strategic Channel Partnerships: Establishing formal Channel Partner agreements to expand the test's reach without massive direct sales investment.

To be fair, the company's minimal revenue in 2025 suggests this channel is still in the developmental and pilot phase, not yet a major commercial driver.

Long-term, strategic relationships with pharmaceutical and biotech partners

Aditxt's most financially significant relationships are with its portfolio companies, which it treats as strategic partners within its business acceleration platform. This model is less about a traditional customer-vendor dynamic and more about a long-term, financial, and operational alliance.

The relationship is defined by deep financial commitment and strategic oversight, exemplified by the company's involvement with Evofem Biosciences, Inc. (Evofem). Aditxt holds preferred stock in Evofem with an aggregate stated value of $26,280,000, plus convertible notes totaling $3,730,769, as of late 2025. This is defintely a partnership of necessity and mutual strategic interest.

Strategic Partner Type	Relationship Goal (2025 Focus)	Key Financial/Strategic Data
Subsidiary/Portfolio Companies (e.g., Evofem)	Business acceleration, regaining national exchange listing, and securing growth capital.	Preferred Stock Stated Value: $26,280,000; Convertible Notes: $3,730,769.
Acquisition Targets (e.g., Appili Therapeutics, Inc.)	Platform expansion into new health verticals like infectious diseases.	Extension of agreement through the end of March 2025.

Direct-to-consumer engagement for personalized health insights

The direct-to-consumer (D2C) relationship is primarily channeled through the precision diagnostics subsidiary, Pearsanta, Inc., which is expected to launch commercially in the second half of 2025. This engagement is transactional but also highly personalized, focusing on early detection of major health issues.

The personalized health insights model centers on:

• High-Value Diagnostics: Offering blood-based tests for conditions like Prostate Cancer and Endometriosis, a global market estimated at $1.45 Billion.
• Empowering Clinicians: The D2C model is likely a 'physician-ordered' model, where the consumer is engaged directly with the insights, but the test is ordered and interpreted by a healthcare professional.
• Funding the Launch: The company authorized exploring an Initial Public Offering (IPO) for Pearsanta in 2025, engaging Dominari Securities LLC as the lead underwriter, to fund this commercialization and global expansion.

Investor relations focused on long-term platform value and clinical milestones

For a company with a net loss of $(37,555,792) for the nine months ended September 30, 2025, investor relations is a critical customer relationship, essentially serving as a primary source of capital. The relationship is one of transparency and long-term vision-casting, given the substantial doubt about the company's ability to continue as a going concern.

The company maintains this relationship through:

• Proactive Communication: Launching the 'Aditxt Weekly Update' series starting March 21, 2025, to provide continuous insight into strategic directions and corporate relationships.
• Platform Vision: Focusing on the bitXbio™ ecosystem, which includes a planned Digital Asset Treasury (DAT) and a native utility token. The goal is to evolve the relationship from a traditional shareholder-company dynamic to a globally participatory life sciences platform.
• Milestone Reporting: Highlighting clinical progress, such as the subsidiary Adimune's positive pre-clinical results from Mayo Clinic studies in April 2025 to support future human trials for Type 1 Diabetes and Psoriasis.

This is a relationship where the company must constantly sell the future value, leveraging clinical milestones to offset current financial distress.

Aditxt, Inc. (ADTX) - Canvas Business Model: Channels

You're looking at Aditxt, Inc.'s channels, and the quick takeaway is this: the company's current channels are less about high-volume product sales and more about strategic intellectual property (IP) development and corporate transactions. Given the total sales revenue of only $2,770 for the nine months ended September 30, 2025, the traditional sales and digital channels are essentially in a pre-commercial or negligible-revenue phase right now.

Direct sales force targeting specialty clinics and hospitals

The direct sales channel for the AditxtScore platform is currently minimal, reflecting the company's focus on its larger innovation platform strategy. AditxtScore, which provides personalized immunity monitoring, is primarily offered through authorized channel partners, not a massive internal sales team. The total sales revenue for the first nine months of fiscal year 2025 was a mere $2,770, which is a substantial decrease from the $130,810 reported for the same period in 2024. This channel is a trickle, not a flood. The minimal revenue suggests that any existing direct sales force is small and focused on pilot programs or securing initial reference accounts, rather than driving scale.

Licensing agreements with global diagnostic and pharmaceutical companies

This channel is a key long-term monetization strategy, even if it's not generating large upfront payments yet. Aditxt's core value proposition is built on its IP, particularly through its Adimune subsidiary, which holds an impressive portfolio of 96 granted and 22 pending patents. The company is actively pursuing monetization through 'licenses' and 'spin-offs.' [cite: 16 (from previous search)] A concrete cost for this channel is the annual licensing maintenance fee for its Stanford University patent, which increased to $60,000 starting in 2025. [cite: 14 (from previous search)] The termination of the Appili Therapeutics, Inc. arrangement in May 2025 shows the volatility in this channel, but the proposed merger with Evofem Biosciences, Inc. (focused on women's health) remains a key corporate channel for expansion in the second half of 2025.

Here's the quick math on the IP channel's current financial footprint:

Channel Component	2025 Financial Impact/Status	Notes
Stanford License Fee	$60,000 annual maintenance fee	A fixed cost for core AditxtScore IP. [cite: 14 (from previous search)]
Adimune IP Portfolio	96 granted, 22 pending patents	Represents future licensing potential in the $160+ billion autoimmune market.
Appili Therapeutics Deal	Terminated in May 2025	Indicates a strategic shift away from that infectious disease focus.
Evofem Merger	Targeted to close in H2 2025	A key corporate channel for portfolio expansion into women's health.

Online portal and mobile application for AditxtScore results delivery

The digital channel is a critical part of the value delivery, but not a significant revenue stream in 2025. The AditxtScore online portal and mobile application serve as the primary means for users to receive their personalized immunity monitoring results. This digital infrastructure is an enabler for the 'authorized channel partners' who actually sell the test. While the platform is functional, user engagement metrics and transaction volumes are not publicly disclosed and are likely very low, given the nine-month sales revenue of under $3,000. The platform is owned by the subsidiary Pearsanta, Inc., which is moving toward a commercial launch of new blood-based diagnostics in the second half of 2025. This channel is currently a cost center and a delivery mechanism, not a sales engine.

Scientific conferences and publications to reach key opinion leaders

This channel is where Aditxt is most active and visible in 2025, focusing on building credibility and awareness among key opinion leaders (KOLs) and the investment community. This is defintely a pre-commercial channel. The goal is to establish the scientific foundation necessary to support future commercialization and licensing deals. Key activities include:

• Announcing positive results from Mayo Clinic pre-clinical studies for its Adimune subsidiary in April 2025.
• Preparing for FDA submission and approval for first-in-human trials for the lead therapeutic candidate, ADI-100, by early 2026.
• Presenting at investor-focused events, such as the Wall Street Reporter's NEXT SUPER STOCK Livestream in June 2025.

This channel is a crucial investment in future revenue, mapping near-term R&D milestones to long-term market opportunity, specifically targeting the global autoimmune therapeutics market, which is projected to exceed $160 billion by 2030.

Aditxt, Inc. (ADTX) - Canvas Business Model: Customer Segments

You're looking at Aditxt, Inc.'s strategy, and the first thing to grasp is that their customer base is highly diversified, spanning from large pharmaceutical partners to individual consumers. This multi-pronged approach is necessary because the company is essentially an innovation platform with several distinct, early-stage subsidiaries, so they have to target multiple revenue streams at once.

To be fair, the company's reported sales for the nine months ended September 30, 2025, were only $2,770 (or $0.00277 million), reflecting a business model still heavily focused on research and development, not mass commercialization. Still, the customer segments are clearly defined by the long-term potential of their pipeline assets like Adimune and Pearsanta. Their strategy is to capture value across the entire health spectrum.

Pharmaceutical and biotech companies seeking novel therapeutic targets

This segment represents the high-value, long-term opportunity for Aditxt, Inc.'s platform technology, particularly through its subsidiary, Adimune. These companies are potential partners for licensing, co-development, or acquisition of the Apoptotic DNA Immunotherapy (ADi) platform.

The core proposition here is a novel class of therapeutics designed to restore immune tolerance without the long-term risks of immunosuppression. The company is actively developing its lead drug candidate, ADI-100, for conditions like Type 1 Diabetes and Psoriasis. They are targeting a global autoimmune therapeutics market that is estimated to reach over $160 billion by 2030. This is the big payoff customer.

• Primary Need: Novel, non-immunosuppressive drug candidates.
• Key Product: ADI-100 (in development for Type 1 Diabetes, Psoriasis, Stiff Person Syndrome).
• Actionable Insight: Monetization will come via clinical trial milestones, licensing agreements, or a strategic sale of the Adimune subsidiary.

Specialty clinicians (e.g., transplant, autoimmune) and hospitals

Specialty clinicians and major medical centers are crucial partners for both therapeutic development and diagnostic adoption. They serve as key opinion leaders (KOLs) and early adopters who can validate the technology and drive initial clinical use. This segment is where the company builds clinical credibility.

For example, Adimune is collaborating with the Mayo Clinic on an Investigational New Drug (IND) application for ADI-100 in Stiff Person Syndrome (SPS) in the U.S.. The initial applications of the AditxtScore platform were also designed to help the medical community anticipate immune responses to transplanted organs, viruses, and bacteria, making transplant centers and infectious disease clinics a primary target. The company operates a CLIA-certified, CAP-accredited lab in Richmond, Virginia, to service these high-complexity testing needs.

Individual consumers interested in personalized immune health monitoring

This segment is served by the precision diagnostics subsidiary, Pearsanta, Inc., and the AditxtScore platform, which focuses on personalized immune health monitoring. The goal is to shift from reactive disease management to proactive, preventative health tracking.

Pearsanta is advancing toward a commercial launch in the second half of 2025 with blood-based tests, starting with Prostate Cancer and Endometriosis. The Endometriosis test, for instance, is targeting a condition affecting an estimated 190 million women worldwide and represents a $1.45 billion global market opportunity for diagnostics. This consumer segment demands direct-to-consumer or physician-ordered tests, a very different sales channel compared to the pharmaceutical segment.

Here's the quick math on the current sales reality versus the consumer market opportunity:

Subsidiary/Program	Target Market	2025 Financial Metric (Reported)	Target Market Size/Value
Adimune (Therapeutics)	Autoimmunity/Pharma	Minimal/R&D Phase	>$160 Billion (Autoimmunity by 2030)
AditxtScore (Diagnostics)	Consumer/Clinician	Q2 2025 Revenue: $1,004	N/A (Broad Immune Health)
Pearsanta (Diagnostics)	Consumer/Women's Health	Minimal/Pre-Commercial Launch	$1.45 Billion (Endometriosis Global Market)

Research institutions and government agencies

This segment acts as a source of intellectual property (IP), a partner for clinical validation, and a potential buyer for large-scale diagnostic services. The company's foundation is built on this relationship; the initial AditxtScore technology was licensed from Stanford University.

Government and institutional customers are primarily interested in the AditxtScore's ability to monitor population health and vaccine efficacy. The platform can help other organizations track the effectiveness of vaccine protocols by monitoring the patient's immune response, a service essential for public health agencies and large research consortia. Their acquisition strategy, including the proposed integration of Appili Therapeutics, Inc., which focuses on infectious diseases, further expands their offering into the public health domain.

The company's model is an ecosystem designed to accelerate health innovations, so defintely, research collaborations are a core component, even if they don't drive significant near-term revenue. This segment is about IP and validation.

Aditxt, Inc. (ADTX) - Canvas Business Model: Cost Structure

The cost structure for Aditxt, Inc. is a classic biotech profile: high fixed costs dominated by research and development (R&D) and significant general and administrative (G&A) overhead, especially for public company compliance. The company is currently spending cash at a rate of over $16.4 million in operating activities for the first nine months of 2025 alone, which is the real cost driver you need to focus on. Their business model is a fixed-cost play, where the high upfront investment is designed to be recovered only if the core intellectual property (IP) for Adimune and AditxtScore achieves commercialization.

Here's the quick math on the operational burn rate, excluding a major one-time event. The total net loss for the nine months ended September 30, 2025, was a staggering $37,555,792. While this number is heavily skewed by a $23,001,919 impairment charge on an investment, the cash used in operations-which represents the true, ongoing cost of running the business-was still $16,442,686. That's a serious burn rate, and it highlights the immense upfront capital required to be a clinical-stage biotech.

Cost Component (Nine Months Ended Sep 30, 2025)	Amount (USD)	Notes
Cash Used in Operating Activities	$16,442,686	Primary measure of ongoing cash burn.
Net Loss	$37,555,792	Includes non-cash items like the impairment charge.
Cost of Goods Sold (COGS)	$2,471	Minimal, reflecting negligible product sales.

Heavy investment in Research and Development (R&D) for clinical trials

The entire enterprise is built on R&D, and this is where the long-term value is created, even if the current spending is not explicitly broken out in the latest nine-month summary. The bulk of the operational cash burn is directed toward advancing the Adimune therapeutic programs and the AditxtScore diagnostic platforms. This R&D investment is a non-negotiable fixed cost for a company with a pre-revenue platform and is the lifeblood of the business. You simply can't cut this without killing the value proposition entirely.

The cost structure is heavily weighted toward scientific personnel, lab resources, and the external costs of running clinical and pre-clinical studies, which are inherently expensive and unpredictable. This cost is a necessary bet on the future of immune modulation technology.

Costs associated with maintaining and defending Intellectual Property (IP)

For a company like Aditxt, IP is the only asset that truly matters, so the costs to maintain and defend it are substantial, though often buried in the General and Administrative (G&A) or legal line items. The cost isn't just filing patents; it's the legal expense of ensuring freedom to operate and defending against infringement, which can run into the millions of dollars quickly for complex biotech patents. To be fair, this cost is a massive barrier to entry for competitors.

You should also be aware of the risk factor mentioned in their filings: a portion of their IP may be subject to 'march-in' rights by the U.S. federal government. This is a potential future cost or loss of exclusivity that must be factored into the risk model, even if it doesn't show up as an expense today.

General and administrative expenses, including public company compliance

This is the second major fixed cost bucket, and it's disproportionately large relative to the company's minimal sales of only $2,770 for the first nine months of 2025. Being a publicly traded company on the Nasdaq Capital Market (NasdaqCM) adds significant, non-discretionary costs. For the second quarter of 2025 alone, General and Administrative costs totaled $5.0 million [cite: 1 from previous step], which dominated the operating expenses for that period.

The costs here are largely for professional fees-legal, accounting, investor relations, and executive compensation-all necessary to maintain a public listing and comply with U.S. Securities and Exchange Commission (SEC) regulations. For example, professional fees were approximately $2.9 million in Q2 2025 [cite: 1 from previous step], which is a massive outlay for a company with virtually no revenue. This high G&A is a clear sign of a company in the R&D and strategic-restructuring phase, not a commercial one.

• Legal and audit fees for SEC filings and reporting.
• Executive and administrative salaries and benefits.
• Stock exchange listing fees and investor communication costs.
• Costs associated with constant capital raising initiatives [cite: 1 from previous step].

Manufacturing and supply chain costs for AditxtScore kits and Adimune

Currently, the costs associated with manufacturing and supply chain are negligible, which is a key indicator of the company's stage. The Cost of Goods Sold (COGS) for the nine months ended September 30, 2025, was only $2,471 [cite: 2, calculation from previous thought], which is barely a rounding error in the overall cost structure. This low figure confirms that commercial-scale production of AditxtScore kits and Adimune is not yet underway.

The risk here is that once the products move into commercialization, this cost will rapidly escalate and become a major variable cost. For now, the manufacturing costs are largely fixed costs related to process development, quality control systems, and securing supply chain agreements, not the variable cost of mass production.

Finance: Track R&D and G&A as a percentage of total operating cash burn quarterly to monitor cost-control effectiveness.

Aditxt, Inc. (ADTX) - Canvas Business Model: Revenue Streams

The revenue model for Aditxt, Inc. in late 2025 is overwhelmingly concentrated in a single, minimal revenue stream from diagnostic services, while the company's core value-its therapeutic platform-remains pre-revenue. For the nine months ended September 30, 2025, the company reported total sales of only $2,770, a sharp decline from the prior year, making it essentially a clinical-stage biotech that relies on financing, not sales, to operate.

Sales of the AditxtScore immune monitoring test kits and services

This is the company's primary, albeit very limited, source of recognized revenue. The AditxtScore is a service that provides a comprehensive immune profile by analyzing patient specimens in the company's CLIA-certified laboratory in Richmond, Virginia.

The revenue generated from these sales, which includes the test kits and the resulting analysis service, is minimal, reflecting a significant drop-off in commercial activity. For the first nine months of the 2025 fiscal year, total sales revenue was only $2,770. To be fair, this is a clear signal that the business model has shifted from a commercial diagnostic focus to a pure R&D platform relying on capital raises, not product sales.

Here's the quick math on the sales performance:

Period	Sales Revenue	Note
Nine Months Ended Sep 30, 2025	$2,770	Total sales reported.
Three Months Ended Jun 30, 2025	$1,004	Quarterly sales reported.
Nine Months Ended Sep 30, 2024 (Prior Year)	$130,810	Represents a significant year-over-year decline.

Potential milestone payments and royalties from Adimune licensing deals

While the subsidiary Adimune, Inc. is the company's most valuable asset, focusing on immune modulation therapeutics like Apoptotic DNA Immunotherapy (ADI), it is currently a pre-revenue venture. The company holds a substantial intellectual property (IP) portfolio of 96 granted and 22 pending patents, which is the foundation for future licensing and royalty revenue.

However, no milestone or royalty payments were recognized as revenue in the reported 2025 financial periods. Adimune's lead candidate, ADI-100, is still in the development phase, with plans to seek FDA submission for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026. So, while this is a critical potential revenue stream, it is defintely not a current one.

Research grants and strategic collaboration fees

Similar to the Adimune licensing stream, there is no quantifiable, recognized revenue from research grants or strategic collaboration fees in the reported 2025 sales figure of $2,770. The company has a history of pursuing collaborations, but these agreements have not translated into material revenue for the first nine months of 2025.

The opportunity here is real, though. The subsidiary Pearsanta, which focuses on mitochondrial DNA technology for early cancer detection, is actively pursuing external funding. This includes an invitation to submit a full proposal for a U.S. Department of Defense grant focused on its Mitomic Ovarian Test. Securing a large grant would be a non-dilutive source of capital, but it would likely be classified as a deferred revenue or a liability until earned, not a sales revenue stream.

Service revenue from custom immune profiling projects

This revenue stream is essentially the core of the reported sales. The total sales revenue of $2,770 for the nine months ended September 30, 2025, is primarily derived from the provision of immune monitoring services, which are custom immune profiling projects for clients. This includes the AditxtScore service, which provides detailed reports on an individual's immune status.

The minimal revenue indicates that the company is not currently focused on scaling its commercial lab services but rather on maintaining its R&D platform while seeking a strategic shift. What this estimate hides is the fact that the company is operating at a severe loss, with a net loss of $37,555,792 for the same nine-month period, demonstrating that current sales are nowhere near covering operating expenses.

• Total 2025 Service Revenue (9 months): $2,770.
• Services involve analysis in the CLIA-certified, CAP-accredited lab.
• Revenue is primarily from AditxtScore services.